| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.
Authors: Salazar R, Capdevila J, Laquente B, Manzano J, Pericay C, Villacampa M, Lopez C, Losa F, Safont M, Gomez A, Alonso V, Escudero P, Gallego J, Sastre J, Gravalos C, Biondo S, Palacios A, Aranda E
BMC Cancer, 2015;15(0):60.
Species: Human
Sample Type: Plasma
Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
Authors: Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz L, Morosi C, Crippa F, Fare E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud F, Salvioni R, Daidone M, Gianni A, Mariani L
Br J Cancer, 2014;110(1):26-33.
Species: Human
Sample Type: Plasma
Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
Authors: Sallinen H, Heikura T, Koponen J, Kosma V, Heinonen S, Yla-Herttuala S, Anttila M
BMC Cancer, 2014;14(0):696.
Species: Human
Sample Type: Serum
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
Authors: Somlo G, Atzori F, Strauss L, Geese W, Specht J, Gradishar W, Rybicki A, Sy O, Vahdat L, Cortes J
Clin Cancer Res, 2013;19(7):1884-93.
Species: Human
Sample Type: Plasma
Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.
Authors: Briasoulis, Evangelo, Aravantinos, Gerasimo, Kouvatseas, George, Pappas, Periklis, Biziota, Eirini, Sainis, Ioannis, Makatsoris, Thomas, Varthalitis, Ioannis, Xanthakis, Ioannis, Vassias, Antonios, Klouvas, George, Boukovinas, Ioannis, Fountzilas, George, Syrigos, Kostanti, Kalofonos, Haralamb, Samantas, Epaminon
BMC Cancer, 2013;13(1):263.
Species: Human
Sample Type: Plasma
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
Authors: Jurgensmeier J, Schmoll H, Robertson J, Brooks L, Taboada M, Morgan S, Wilson D, Hoff P
Br J Cancer, 2013;108(6):1316-23.
Species: Human
Sample Type: Plasma
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
Authors: Widemann B, Kim A, Fox E, Baruchel S, Adamson P, Ingle A, Glade Bender J, Burke M, Weigel B, Stempak D, Balis F, Blaney S
Clin Cancer Res, 2012;18(21):6011-22.
Species: Human
Sample Type: Plasma
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
Br. J. Cancer, 2012;107(4):639-45.
Species: Human
Sample Type: Serum
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Authors: Loupakis F, Cremolini C, Fioravanti A
Br. J. Cancer, 2011;104(8):1262-9.
Species: Human
Sample Type: Plasma
Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
Authors: Farace F, Gross-Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, Billiot F, Mauguen A, Hill C, Escudier B
Br. J. Cancer, 2011;104(7):1144-50.
Species: Human
Sample Type: Plasma
Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept.
Authors: de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, Deangelis L, Camphausen K, Chen A, Yung W, Prados M, Wen PY, Heymach JV
Clin. Cancer Res., 2011;17(14):4872-4881.
Species: Human
Sample Type: Plasma
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
Authors: Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, Lim HY, Kim JS, Lechuga MJ, Lanzalone S, Lin X, Faivre S
J Transl Med, 2011;9(0):120.
Species: Human
Sample Type: Plasma
Prognostic significance of angiogenic factors in uterine cervical cancer.
Authors: Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kummel S
Anticancer Res., 2011;31(8):2589-95.
Species: Human
Sample Type: Serum
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a childrens oncology group study.
Authors: Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM
Clin. Cancer Res., 2011;17(15):5113-22.
Species: Human
Sample Type: Plasma
Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis.
Authors: Bourlev V, Iljasova N, Adamyan L, Larsson A, Olovsson M
Fertil. Steril., 2010;94(1):52-7.
Species: Human
Sample Type: Serum
Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.
Authors: Konings IR, de Jonge MJ, Burger H
Br. J. Cancer, 2010;103(7):987-92.
Species: Human
Sample Type: Serum
Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.
Authors: Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S
Mol. Ther., 2009;17(2):278-84.
Species: Human
Sample Type: Plasma
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Authors: Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK
J. Clin. Oncol., 2009;27(18):3027-35.
Species: Human
Sample Type: Plasma
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Authors: Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD
J. Clin. Oncol., 2008;26(11):1810-6.
Species: Human
Sample Type: Plasma
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
Authors: Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ
J. Clin. Oncol., 2007;25(30):4793-9.
Species: Human
Sample Type: Plasma
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
Authors: Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV
Clin. Cancer Res., 2007;13(9):2643-50.
Species: Human
Sample Type: Plasma
Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction.
Authors: Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D
Clin. Sci., 2007;112(1):51-7.
Species: Human
Sample Type: Serum
|
